ABSTRACT We have provided evidence for the existence of a biologically active opioid in toad (Bufo marinus) brain that is immunoreactive with antiserum raised against dynorphin-(1-13). Compared with porcine dynorphin, this opioid is similar in apparent molecular weight on the basis of gel permeation chromatography and is more hydrophobic on the basis of high-performance liquid chromatography. After purification, its opioid biological activity was demonstrated on the guinea pig ileum myenteric plexus-longitudinal muscle preparation. It was found to be less potent, and to have a similar sensitivity to antagonism by naloxone, in comparison with porcine dynorphin. Because it is immunoreactive with antiserum specific for porcine dynorphin, it probably has considerable sequence homology. Generally, the tissue distribution ofimmunoreactive dynorphin in the toad is similar to that in the rat, with highest concentrations in the neurointermediate lobe of the pituitary. However, the anterior lobe of the toad pituitary contains considerably lower concentrations than are found in the rat anterior lobe. There appear to be three size classes of immunoreactive dynorphin in toad neural tissue, each with apparent molecular weight below 12,000, similar to the size classes of immunoreactive dynorphin found in pig and rat. However, in toad spinal cord (and possibly in brain) there is immunoreactive dynorphin of greater apparent molecular weight, which has not been reported in mammalian tissue. The contribution of each molecular size to the total immunoreactivity varies from tissue to tissue and is different from that observed in the rat.
Dynorphin is a potent opioid heptadecapeptide, initially purified from porcine pituitary and found to contain the [Leu] enkephalin sequence at its amino terminus (1, 2) . Using antiserum ("Lucia") raised against dynorphin-(1-13) (D13) and specific for the sequence dynorphin- (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (3) , immunoreactive dynorphin (ir-Dyn) has been found in pig, beef, and rat pituitary and rat brain and spinal cord (4) (5) (6) (7) . This paper describes the presence of ir-Dyn in toad (Bufo marinus) pituitary, brain, and spinal cord. We determined the tissue content and molecular size distribution patterns and reported these results in preliminary form (8) . Then, using highperformance liquid chromatography (HPLC), we partially purified the toad brain ir-Dyn closest in apparent molecular weight to that of porcine dynorphin and found that it had typical opioid activity in the guinea pig ileum myenteric plexus-longitudinal muscle (GPI) preparation. The substance is recognized by our specific dynorphin antiserum, but it differs somewhat from porcine dynorphin.
MATERIALS AND METHODS
The following opioid peptides were synthesized by Peninsula Laboratories (San Carlos, CA): porcine dynorphin, D13, a-neoendorphin,* and camel ,B3endorphin ((3-endorphin) . Each peptide was eluted as a single peak on HPLC. Normorphine was obtained from Applied Science (State College, PA), naloxone hydrochloride was from Endo Laboratories (Garden City, NJ). Iodinated peptides were prepared by a modification of the method of Hunter and Greenwood (10) , separated from unreacted iodide on a Bio-Gel P-2 column (0.7 x 20 cm; Bio-Rad) with methanol/glacial acetic acid/water, 300:275:1,100 (vol/ vol), and purified by HPLC as described (2) . Unless otherwise noted, reagents were Baker analyzed reagent grade.
Adult male Bufo marinus (200-300 g) were obtained from Carolina Biologicals (Burlington, NC) or Charles Sullivan (Nashville, TN). Tissues from brain, spinal cord, and pituitary were removed immediately after decapitation, dissected on a chilled aluminum plate, and quickly frozen in powdered dry ice. Meningeal tissue and cerebellum were discarded, and the brain was cut posteriorly at the level of the obex. Anterior and neurointermediate lobe (NIL) ofpituitary were separated under a dissecting microscope.
Tissues were extracted as described in the legends to Table  1 and Fig. 1 , assayed by radioimmunoassay (RIA), and characterized by Sephadex G-50 chromatography.
CM-Sephadex (C-25, Pharmacia, prewashed with 1 M HCl, 1 M NaOH, 0.5 M acetic acid, and 0.1 M acetic acid) was used for concentrating and desalting Sephadex G-50 fractions containing the peak of ir-Dyn nearest the salt volume. Fractions were mixed with 0.2 ml ofCM-Sephadex in Bio-Rad disposable columns at 4°C, and the solvent was removed by filtration. The gel was washed twice with 10 ml of distilled water, and ir-Dvn was eluted at room temperature with five 100-,ul portions of methanol/0.5 M HCl, 1:1 (vol/vol). Recovery of ir-Dvn was typically 90% or better.
CM-Sephadex concentrates from toad brain were characterized on a reverse-phase HPLC column as described in the legend to Fig. 2 . Peak ir-Dyn fractions were lyophilized, then pooled in a small volume of methanol/0. 1 M HCl, 1:1 (vol/vol) (referred to hereafter as MeOH/HCl). Recovery ofir-Dvn after HPLC purification was typically 40-60%.
HPLC-purified material was further purified by extraction with immunoaffinity gel [Sepharose-4B coupled to Lucia antibodies as described by Goldstein et al (2) ]. Details of the procedure are presented in the legend to Fig. 4 .
For estimation of ir-Dyn by RIA, Lucia antiserum and 125I-labeled D13 (125I-D13) were prepared and incubated with the sample as described (3) . In order to provide a direct method of assay throughout the purification, the reagent composition of The GPI preparation was used as described (11) to assess opioid bioactivity after HPLC and immunoaffinity extraction. Inhibition less than 15% or greater than 85% of the initial contraction height was not included in calculations. Dilutions were made in MeOH/HCl. The concentration of ir-Dyn necessary for 50% inhibition of muscle contraction (ICs5) was estimated by interpolation of measurements bracketing 50% on a plot of percent inhibition as a function of concentration (on a logarithmic scale). The IC' estimates for determining naloxone K1 were obtained by extrapolation as explained in the legend to Table 2 .
RESULTS
Tissue concentrations ofir-Dyn were highest in the NIL of toad pituitary and lowest in the anterior lobe ( Table 1) . The values in anterior lobe were sufficiently low to suggest that measurable ir-Dyn might have been the result of tissue contamination from NIL. The concentrations ofir-Dyn in toad brain and spinal cord were approximately 1% that in NIL (Table 1) . Total ir-Dyn was equally distributed between whole brain and NIL.
Four peaks of ir-Dyn were observed after Sephadex G-50 gel permeation chromatography of toad neural tissue extracts ( (16 ,000 x g, 20 min, 4C). Supernatant solutions larger than 6 ml were concentrated by lyophilization and resuspension in 1 M acetic acid containing 0.1% Triton X-100. Routinely, 2.9 ml of the supernatant solution was applied to a Sephadex G-50 fine column (Pharmacia; 90 x 1.5 cm; elution solvent 0.1 M acetic acid in 0.15 M NaCl with 0.1% Triton X-100), then eluted at 5-7 ml/hr at 40C. Fractions (2.0 ml) were collected, and samples were removed for determination of ir-Dyn. Markers CH3CN) . The CM-Sephadex concentrate of toad brain peak D (54.2 pmol of ir-Dyn) was applied to the column and eluted as one major peak (D') 27.6 min after the start of the gradient (30.4% CH3CN). Recovery of ir-Dyn from the column was 52.8%. The minor peak of ir-Dyn that eluted 24 min after the start of the gradient (29.6% CH3CN) represented 8% of the ir-Dyn applied to the column. A second and steeper gradient from 35% to 90% CH3CN in 30 min (not shown), yielded no more ir-Dyn. ir-Dyn was less than 0.3 pmol per fraction after HPLC of blank preparations extracted in the same manner as tissue and carried through the purification. The retention times of peak D' and iodinated markers did not vary by more than 2.4 min in six additional HPLC characterizations in which 300 toad brains were purified (in batches of 50) as described in Materials and Methods. Once this purification was completed, the HPLC column was calibrated further. Porcine dynorphin (12.1 pmol, based on RIA estimate) was applied to the column, and eluted, as shown, in a single peak 20.8 min after the start of the gradient (28.8% CH3CN). Recovery of ir-Dyn from the column was 54.6%. a-Neo-endorphin and l3c-endorphin were applied to the column separately, and were eluted as single peaks 8 and 45 min after the start of the CH3CN gradient (26% and 35% CH3CN), respectively, based on absorbance at 228 nm.
45 min after the start of the CH3CN gradient (26% and 35% CH3CN; Fig. 2 of peak D' may be greater, and hence the potency less, than that indicated here. After immunoaffinity extraction, peak D' inhibited the electrically stimulated twitch in the GPI preparation, and this inhibition was reversed by naloxone (Fig. 3 Lower). If all opioid activity present in peak D' were associated with ir-Dyn, little or no opioid activity should remain in the incubation mixture after immunoextraction; and recoveries of opioid activity and ir-Dyn in the gel extract should be comparable and similar to the recoveries in a known dynorphin extract. These conditions were met for peak D' (Fig. 4) , and therefore it appears that all (or nearly all) opioid activity in peak D' is associated with irDyn. By contrast, with a-neo-endorphin (43 pmol), 125% ofthe initial bioactivity was recovered in the incubation mixture after extraction with immunoaffinity gel (not shown).
Like porcine dynorphin, the opioid bioactivity ofpeak D' was less sensitive to naloxone antagonism than that ofnormorphine, as determined by comparison of the apparent dissociation constants (Ke) for naloxone on the same GPI preparations: 22, 17, and 4 nM for porcine dynorphin, peak D', and normorphine, respectively (Table 2 ).
DISCUSSION
The distribution of ir-Dyn across tissues in the toad is generally similar to that reported for the rat (4) (5) (6) (7) . For (4, 5, 7, 14) . In toad neural tissue, the relative contribution of each molecular size ir-Dyn to the total immunoreactivity varies from tissue to tissue in a pattern different from that seen in the rat. In toad pituitary NIL, peak D (the predominant ir-Dyn) has apparent Mr 1,400-1,800 and is eluted in a position similar to that of porcine pituitary dynorphin (14) . However, the intermediate sized ir-Dyn in porcine and rat pituitary NIL is not present in toad NIL. In toad brain, there are two major molecular size forms of ir-Dyn: peak B (apparent Mr 11,000) is similar to that of porcine pituitary dynorphin. In toad spinal cord, the predominant ir-Dyn, which is eluted in the void volume (Mr 30,000 or greater), is considerably larger than any irDyn found in rat or pig.
Peak D from toad brain, partially purified by HPLC, is eluted as a single peak (peak D'), with a longer retention time than porcine dynorphin. We will refer to this HPLC-purified preparation as "toad dynorphin" for purposes of discussion.
Toad dynorphin inhibits the electrically stimulated twitch of the GPI, and this effect is reversed by the specific opioid antagonist naloxone. Its opioid potency in the bioassay, relative to its dynorphin immunoreactivity, is one-third that of porcine dynorphin. This difference in potency could be even greater, because toad dynorphin may not be fully immunoreactive with the antiserum.
We have shown that the potency of toad dynorphin remains the same after immunoaffinity extraction, and furthermore, that recovery is comparable to that ofporcine dynorphin. Therefore, opioid activity in this preparation is associated with its immunoreactivity to the dynorphin-specific antiserum. The antiserum, as described previously (3) , recognizes the sequence dynorphin-(3-12), and does not crossreact with [Met] enkephalin, [Leu]enkephalin, a-endorphin, or human (3-endorphin. In addition, it does not crossreact with a-neo-endorphin (unpublished observation).
In the GPI bioassay, toad dynorphin, like porcine dynorphin, is less sensitive to naloxone antagonism than is normorphine, as determined by estimations of the apparent dissociation constants for naloxone. Thus the opioid receptor specificity of toad dynorphin appears to be similar to that of porcine dynorphin.
The retention time of toad dynorphin on reverse-phase HPLC is longer than that ofporcine dynorphin, suggesting that it is more hydrophobic. The longer retention time could not be explained by fragmentation to a biologically active dynorphin peptide shorter than dynorphin- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , because all such fragments have shorter retention times than porcine dynorphin, as judged by their characterization in a similar HPLC system (15) .
Although the retention times on HPLC for dynorphin fragments larger than D13 have not been determined, it is unlikely that any such fragment would account for the difference in opioid potency reported here. D13 and its COOH-terminally extended derivatives have the same potency as porcine dynorphin itself in the GPI (2, 16) . Therefore potency would not be expected to differ for dynorphin fragments larger than D13.
It is likely, therefore, that toad dynorphin has a sequence that differs slightly from that of porcine dynorphin, while retaining enough homology to have similar biological and immunoreactive properties. An analogous example would be the substitution of isoleucine for phenylalanine at position 3 of arginine vasopressin to form vasotocin, the predominant form ofantidiuretic hormone in amphibia (17) .
We have provided evidence for the existence ofa biologically active opioid in toad brain that is immunoreactive with dynorphin-specific antiserum. Its tissue distribution, apparent molecular size, and opioid receptor selectivity are similar to those ofporcine dynorphin. It probably differs somewhat in its amino acid sequence from porcine dynorphin, and this difference may justify isolation and sequence analysis. The lower oxygen demand of amphibian tissue and the somewhat simpler nervous system suggest that the toad may provide a good model for in vitro studies of dynorphin processing and release. Differences in the molecular size forms ofir-Dyn in toad and rat suggest that there may also be species differences in dynorphin processing.
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